MedTrace Logo

Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers

NCT03276858 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2018-08-29

No results posted yet for this study

Summary

This single-center study will be conducted in 3 phases: a single-ascending dose phase (up to 8 cohorts, 8 subjects/cohort), a multiple-dose phase (up to 5 cohorts, 9 subjects/cohort), and a midazolam drug-drug interaction phase (one cohort of 8 subjects).

Conditions

  • Healthy Volunteers

Interventions

DRUG

CRN00808

Investigational drug

DRUG

Placebo Oral Solution

Placebo

DRUG

Midazolam oral solution

Midazolam as part of the drug-drug interaction arm of the study

DRUG

Placebo oral capsule

Placebo

Sponsors & Collaborators

  • Crinetics Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Jason Lickliter, MBBS PhD · Nucleus Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-22
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03276858 on ClinicalTrials.gov